Provention Bio, Inc.
PRVBDelisted Apr 27, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001695357
Provention Bio, Inc. was delisted on Apr 27, 2023; its insiders filed their last Form 4 on Apr 28, 2023; 183 institutions reported holding it in 13F filings for Q1 2023, worth $1.47B in total; Fairfax Financial was the only superinvestor holding it.
13F holders, Q3 2022
Institutional positions in Provention Bio, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 112
- −3 vs. Q2 2022
- Shares held
- 41.6M
- +16.6M (+66.4%) vs. Q2 2022
- Total value
- $187.1M
- +$87.1M (+87.2%) vs. Q2 2022
- New holders
- 11
- 51 more added
- Sold out
- 14
- 18 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PRVB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 1 | $2.80M |
| Q1 2023 | 183 | $1.47B |
| Q4 2022 | 133 | $477.4M |
| Q3 2022 | 112 | $187.1M |
| Q2 2022 | 115 | $99.9M |
| Q1 2022 | 113 | $177.0M |
| Q4 2021 | 112 | $133.0M |
| Q3 2021 | 115 | $142.9M |
| Q2 2021 | 125 | $196.9M |
| Q1 2021 | 120 | $249.3M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Provention Bio, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Palo Alto Investors LP | 390,800 | $1.76M | 0.14% | +390,800 | New |
| DG Capital Management, LLC | 499,271 | $2.25M | 1.04% | −123,297−19.8% | Reduced |
| Northern Trust Corp | 565,062 | $2.54M | 0.00% | +47,930+9.3% | Added |
| MPM Oncology Impact Management LP | 740,344 | $3.33M | 0.79% | +147,909+25.0% | Added |
| Verition Fund Management LLC | 867,165 | $3.90M | 0.05% | −93,298−9.7% | Reduced |
| VR Adviser, LLC | 1,118,653 | $5.03M | 0.78% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 1,196,797 | $5.38M | 0.00% | +241,548+25.3% | Added |
| State Street Corp | 1,294,425 | $5.83M | 0.00% | +85,236+7.0% | Added |
| Vanguard Group Inc | 3,604,065 | $16.2M | 0.00% | +1,027,113+39.9% | Added |
| BlackRock Inc. | 5,030,348 | $22.6M | 0.00% | +424,311+9.2% | Added |
| Adage Capital Partners GP, L.L.C. | 5,770,000 | $26.0M | 0.06% | +4,870,000+541.1% | Added |
| Sessa Capital IM, L.P. | 14,879,023 | $67.0M | 4.78% | +8,879,023+148.0% | Added |
| Jump Financial, LLC | 0 | $0 | 0.00% | −55,461−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −45,043−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −42,540−100.0% | Sold out |
| Delphia (USA) Inc. | 0 | $0 | 0.00% | −25,698−100.0% | Sold out |
| Corton Capital Inc. | 0 | $0 | 0.00% | −23,548−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −17,775−100.0% | Sold out |
| Cetera Investment Advisers | 0 | $0 | 0.00% | −13,800−100.0% | Sold out |
| Prelude Capital Management, LLC | 0 | $0 | 0.00% | −12,064−100.0% | Sold out |
| Aspiriant, LLC | 0 | $0 | 0.00% | −11,000−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −10,542−100.0% | Sold out |
| Old Mission Capital LLC | 0 | $0 | 0.00% | −10,283−100.0% | Sold out |
| Point72 Hong Kong Ltd | 0 | $0 | 0.00% | −5,184−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −3,000−100.0% | Sold out |
| Massmutual Trust Co FSB | 0 | $0 | 0.00% | −107−100.0% | Sold out |